Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Практические аспекты применения фиксированных комбинаций в лечении артериальной гипертензии
Практические аспекты применения фиксированных комбинаций в лечении артериальной гипертензии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Артериальная гипертензия – ведущая причина возникновения инфарктов и инсультов. Достижение целевого уровня артериального давления (АД) при артериальной гипертензии является основным условием оптимизации прогноза в отношении сердечно-сосудистой заболеваемости и смертности. Для решения этой задачи значительная часть больных нуждаются в применении антигипертензивных препаратов, при этом у 70–80% целевой уровень АД может быть достигнут при использовании комбинированной терапии. Фиксированные комбинации антигипертензивных препаратов повышают приверженность пациентов лечению и обеспечивают лучшую органопротекцию. Новая фиксированная комбинация высокоселективного b-адреноблокатора бисопролола и антагониста кальция амлодипина позволяет достичь целевого уровня АД у 82,5% больных при минимальной частоте побочных эффектов.
Ключевые слова: артериальная гипертензия, комбинированная терапия, фиксированные комбинации, бисопролол, амлодипин, Конкор АМ.
Key words: hypertension, combination therapy, fixed combinations, bisoprolol, amlodipine, Concor AM.
Ключевые слова: артериальная гипертензия, комбинированная терапия, фиксированные комбинации, бисопролол, амлодипин, Конкор АМ.
________________________________________________
Key words: hypertension, combination therapy, fixed combinations, bisoprolol, amlodipine, Concor AM.
Полный текст
Список литературы
1. Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваск. терапия и профилактика. 2011; 1: 9–14.
2. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3–7.
3. Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
5. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755–62.
6. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393–404.
7. Dahlof B, Devereux RB, Kjedsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995–1003.
8. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure-Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462–536.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood-pressure-lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.
11. Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38–45.
12. Singh BN. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3–G9.
13. Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–21.
14. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61–4.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
16. Broekman CP, Yaensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325–31.
17. Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long-term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.
18. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non-insulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.
19. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the car-dioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122–7.
20. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103–13.
21. Goose P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 145–50.
22. DeMuinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870–5.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9–13.
24. Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.
25. Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321–5.
26. Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administrated with metformin. Diabetes Obes Metab 2003; 5: 424–31.
27. Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: meta-analysis. Hypertension 2010; 55: 399–407.
28. Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225–34.
2. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3–7.
3. Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
5. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755–62.
6. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393–404.
7. Dahlof B, Devereux RB, Kjedsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995–1003.
8. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure-Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462–536.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood-pressure-lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.
11. Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38–45.
12. Singh BN. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3–G9.
13. Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–21.
14. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61–4.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
16. Broekman CP, Yaensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325–31.
17. Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long-term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.
18. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non-insulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.
19. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the car-dioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122–7.
20. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103–13.
21. Goose P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 145–50.
22. DeMuinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870–5.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9–13.
24. Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.
25. Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321–5.
26. Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administrated with metformin. Diabetes Obes Metab 2003; 5: 424–31.
27. Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: meta-analysis. Hypertension 2010; 55: 399–407.
28. Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225–34.
2. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3–7.
3. Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
5. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755–62.
6. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393–404.
7. Dahlof B, Devereux RB, Kjedsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995–1003.
8. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure-Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462–536.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood-pressure-lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.
11. Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38–45.
12. Singh BN. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3–G9.
13. Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–21.
14. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61–4.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
16. Broekman CP, Yaensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325–31.
17. Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long-term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.
18. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non-insulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.
19. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the car-dioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122–7.
20. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103–13.
21. Goose P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 145–50.
22. DeMuinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870–5.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9–13.
24. Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.
25. Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321–5.
26. Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administrated with metformin. Diabetes Obes Metab 2003; 5: 424–31.
27. Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: meta-analysis. Hypertension 2010; 55: 399–407.
28. Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225–34.
________________________________________________
2. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001; 2: 3–7.
3. Здравоохранение в России. 2011. Статистический сборник. М.: Росстат, 2011.
4. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
5. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998; 351 (9118): 1755–62.
6. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393–404.
7. Dahlof B, Devereux RB, Kjedsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trail against atenolol. Lancet 2002; 359 (9311): 995–1003.
8. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial Blood-Pressure-Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
9. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462–536.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood-pressure-lowering drugs: analysis of 354 randomized trials. BMJ 2003; 326 (7404): 1427.
11. Gu Q, Dillon C, Burt V, Gillum R. Association of antihypertensive treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010; 23: 38–45.
12. Singh BN. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003; 5 (Suppl. G): G3–G9.
13. Palatini P et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–21.
14. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991; 68 (1): 61–4.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
16. Broekman CP, Yaensel SM, van de Ven LL, Slob AK. Bisoprolol and hypertension; effects on sexual function in men. J Sex Marital Ther 1992; 18 (4): 325–31.
17. Frithz G. Effects of bisoprolol on blood pressure and serum lipids in the long-term treatment of essential hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 2): 424.
18. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in non-insulin-dependent diabetics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S96–9.
19. Buhler FR, Berglund G, Anderson OK et al. Double-blind of the car-dioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 122–7.
20. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8 (Suppl. M): 103–13.
21. Goose P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effect on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): 145–50.
22. DeMuinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-inducted angina pectoris: a Multicenter International Randomozed Study of Angina pectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19 (6): 870–5.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353 (9146): 9–13.
24. Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd ed. Philadelphia; London: Lippincott Williams & Wilkins 2008.
25. Dusing R. Optimizing blood pressure control through the use of fixed combination. Vasc Health Risc Manag 2010; 6: 321–5.
26. Blonde L, Wogen J, Kreilick C, Seymour A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administrated with metformin. Diabetes Obes Metab 2003; 5: 424–31.
27. Gupta A, Arshad S, Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: meta-analysis. Hypertension 2010; 55: 399–407.
28. Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008; 61 (4): 225–34.
Авторы
М.Ю.Огарков*1, М.Н.Баранова1, А.Е.Скрипченко2
1 ГБОУ ДПО Новокузнецкий государственный институт усовершенствования врачей Минздрава России;
2 ФГБУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний СО РАМН
*ogarmu@cardio.kem.ru
ogarmu@cardio.kem.ru
1 ГБОУ ДПО Новокузнецкий государственный институт усовершенствования врачей Минздрава России;
2 ФГБУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний СО РАМН
*ogarmu@cardio.kem.ru
________________________________________________
ogarmu@cardio.kem.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.